AxRecon(TM) Shortens the Time Required for Drug Development
CALGARY, June 3 /CNW/ - Acceleware Corp. (TSX-V: AXE), a leading
developer of high-performance computing applications, today announced the
adoption of the AxRecon image reconstruction solution for micro-computed
tomography (CT) by a major pharmaceutical company. Eli Lilly, a leading
developer of pharmaceutical products, has selected AxRecon(TM) solution to
speed up image reconstruction times used in the pharmaceutical development
"Our early success in helping pharmaceutical companies reduce time spent
in drug development is encouraging," said Sean Krakiwsky, CEO of Acceleware
Corp. "AxRecon's ability to simply and seamlessly fit with existing CT scanner
hardware and software to deliver results up to 50 times faster makes our
product attractive to medical researchers and other users of CT Scanners."
Pharmaceutical researchers regularly use CT Scanners in the drug
development process to observe the effects of novel drug candidates on
anatomy. However, deriving value from CT Scanners for drug development is
hampered by slow image reconstruction time due to insufficient computing
power. This reduces efficiency as well as the researcher's ability to maximize
the capabilities of advanced imaging equipment. Acceleware's solution
eliminates the computer processing bottleneck in image reconstruction
workflow, and speeds up the evaluation of drug effectiveness.
Acceleware's AxRecon works as a turn-key solution with a low cost of
operation that fits into the current CT Scanner workflow, generating fully
reconstructed, quality images completed hours sooner than before.
Acceleware's application acceleration platform utilizes the power of
NVIDIA(R) Graphic Processing Units (GPUs) to dramatically increase the speed
of sophisticated computations, saving on power and space while maintaining
For more information about the AxRecon solution please visit our website
Acceleware develops and markets solutions that enable software vendors to
leverage heterogeneous, multi-core processing hardware without rewriting their
applications for parallel computing. This acceleration middleware allows
customers to speed-up simulation and data processing algorithms, benefiting
from high performance computing technologies available in the market such as
multiple-core CPUs, GPUs or other acceleration hardware.
Acceleware solutions are deployed by companies worldwide such Philips,
Boston Scientific, Samsung, Eli Lilly, General Mills, Nokia, LG, RIM, Kyocera,
Medtronic, Hitachi, Fujifilm, FDA, Mitsubishi, Sony Ericsson, AGC, NTT DoCoMo,
and Renault to speed up product design, analyze data and make better business
decisions in areas such as electronic manufacturing, oil & gas, medical and
security imaging, industrial and consumer products, and academic research.
Acceleware is a public company on Canada's TSX Venture Exchange under the
trading symbol AXE.
The TSX Venture Exchange Inc. does not accept responsibility for the
adequacy or accuracy of this release.
For further information:
For further information: press only: Liaison Inc., Kerry Tescher, (415)
391-0859, email@example.com; Reader Contact: Charlee Forbrigger, Marketing
Manager at Acceleware Corp., (403) 249-9099 ext. 287,
firstname.lastname@example.org; Investor Contact: Thomas McMillan, The
Equicom Group, (403) 536-5903, email@example.com